承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 董事會召開日期 上海君實生物醫藥科技股份有限公司（「本公司」，及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2026年3月13日（星期五）舉行董事會會議，以考慮及通 過本集團截至2025年12月31日止的年度全年業績，及考慮派發末期股息（如有） 以及處理其他事項。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 中國，上海，2026年3月2日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年3月2日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 （股份代號：1877） 董事會召開日期 上海君實生物醫藥科技股份有限公司（「本公司」，及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2026年3月13日（星期五）舉行董事會會議，以考慮及通 過本集團截至2025年12月31日止的年度全年業績，及考慮派發末期股息（如有） 以及處理其他事項。 ...

1. Report Industry Investment Rating - No industry investment rating is provided in the report. 2. Core Views of the Report - From February 24 to February 27, 2026, all major equity market indices rose, with the CSI 500 having the largest increase of 4.32%. Among the 31 Shenwan primary industries, 25 industries rose, with the top five gainers being steel, non-ferrous metals, chemicals, environmental protection, and coal; the top five decliners were media, commercial trade, food and beverages, non-bank finance, and banks [1][12]. - The CSRC issued the "Administrative Measures for the Supervision of Information Disclosure of Private Investment Funds", which takes effect on September 1, 2026. The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced the adjustment of constituent stocks of key indices such as the STAR 50, to be implemented after the close on March 13, 2026 [2][31][33]. - In terms of fund performance, quantitative funds had the largest increase, with an average increase of 2.22% and a positive return ratio of 92.26%. Fixed - income + funds rose 0.30% on average, with a positive return ratio of 73.12%. Pure - bond funds rose 0.01% on average, with a positive return ratio of 60.51%. Pension target FOFs rose 0.93% on average, with a positive return ratio of 99.50%. QDII funds fell 0.11% on average, with a positive return ratio of 58.16% [2][34]. - The top three sectors with the largest increase in positions of active equity funds last week were media, commerce and retail, and real estate; the top three sectors with the largest decrease in positions were electronics, non - ferrous metals, and pharmaceutical biology. As of February 27, 2026, the overall position of active equity funds was 77.23%, an increase of 0.81 pct from the previous period [2][40][42]. - Last week, the overall ETF market had a net capital outflow of 22.828 billion yuan. Stock - type ETFs had a relatively large net outflow of 36.286 billion yuan. The daily average trading volume of the overall ETF market reached 476.804 billion yuan, the daily average trading volume reached 168.72 billion shares, and the daily average turnover rate was 7.40%. The Hang Seng Technology, power grid equipment, securities, and Internet sectors had net capital inflows, with the Hang Seng Technology having a capital inflow close to 10 billion yuan. Broad - based indices such as the CSI 1000, CSI A500, CSI Small Cap 500, CSI 300, and SSE STAR 50 were the main varieties with capital outflows [3][46][49]. - Last week, 36 new funds were issued, an increase of 28 from the previous period; 5 new funds were established, a decrease of 59 from the previous period. New funds raised a total of 1.451 billion yuan, a decrease of 56.879 billion yuan from the previous period [4][54][59]. 3. Summary According to Relevant Catalogs 3.1 Market Review 3.1.1 Domestic Market Situation - From February 24 to February 27, 2026, all major equity market indices rose, with the CSI 500 rising 4.32%. Among the 31 Shenwan primary industries, 25 industries rose, and 6 industries fell. The top five gainers were steel, non - ferrous metals, chemicals, environmental protection, and coal; the top five decliners were media, commercial trade, food and beverages, non - bank finance, and banks. In the bond market, the ChinaBond Composite Full - Price Index fell 0.14%, and the total full - price indices of ChinaBond Treasury bonds, financial bonds, and credit bonds fell between 0.01% and 0.31%. The CSI Convertible Bond Index fell 0.23%. In the commodity market, the Nanhua Commodity Index rose 3.56% [12]. 3.1.2 European, American, and Asia - Pacific Market Situation - Last week, most major indices in European, American, and Asia - Pacific markets rose. In the US stock market, the S&P 500 rose 0.21%, the Dow Jones Industrial Average rose 0.34%, and the Nasdaq rose 0.18%. In the European market, the French CAC40 rose 0.98%, and the German DAX rose 1.17%. In the Asia - Pacific market, the Hang Seng Index fell 1.67%, and the Nikkei 225 rose 3.56% [20]. 3.1.3 Market Valuation Situation - Last week, the valuation quantiles of most major market indices rose. In terms of the historical quantile of price - to - earnings ratio, the CSI All - Share Index had the largest increase of 8.6 pct. In terms of the historical quantile of price - to - book ratio, the CSI 1000 had the largest increase of 5.4 pct. Among industries, the top five industries with the highest historical quantiles of price - to - earnings ratio of the Shenwan primary index were real estate, electronics, building materials, comprehensive, and chemicals. The price - to - earnings ratio quantile of real estate remained at a high level, and that of electronics reached 96.9%. The bottom five industries with the lowest historical quantiles of price - to - earnings ratio were non - bank finance, agriculture, forestry, animal husbandry and fishery, food and beverages, beauty care, and pharmaceutical biology. The valuation of the non - bank finance industry was close to its historical low since 2013 [23]. 3.2 Active Public - Offering Fund Situation - Market hotspots: The CSRC issued the "Administrative Measures for the Supervision of Information Disclosure of Private Investment Funds", which takes effect on September 1, 2026. The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced the adjustment of constituent stocks of key indices such as the STAR 50, to be implemented after the close on March 13, 2026 [31][33]. - Fund performance: Quantitative funds had the largest increase, with an average increase of 2.22% and a positive return ratio of 92.26%. Fixed - income + funds rose 0.30% on average, with a positive return ratio of 73.12%. Pure - bond funds rose 0.01% on average, with a positive return ratio of 60.51%. Pension target FOFs rose 0.93% on average, with a positive return ratio of 99.50%. QDII funds fell 0.11% on average, with a positive return ratio of 58.16% [34]. - The top three sectors with the largest increase in positions of active equity funds last week were media, commerce and retail, and real estate; the top three sectors with the largest decrease in positions were electronics, non - ferrous metals, and pharmaceutical biology. As of February 27, 2026, the overall position of active equity funds was 77.23%, an increase of 0.81 pct from the previous period [40][42]. 3.3 ETF Fund Situation - Last week, the overall ETF market had a net capital outflow of 22.828 billion yuan. Stock - type ETFs had a relatively large net outflow of 36.286 billion yuan. The daily average trading volume of the overall ETF market reached 476.804 billion yuan, the daily average trading volume reached 168.72 billion shares, and the daily average turnover rate was 7.40%. The Hang Seng Technology, power grid equipment, securities, and Internet sectors had net capital inflows, with the Hang Seng Technology having a capital inflow close to 10 billion yuan. Broad - based indices such as the CSI 1000, CSI A500, CSI Small Cap 500, CSI 300, and SSE STAR 50 were the main varieties with capital outflows [3][46][49]. 3.4 Fund Issuance Statistics - Last week, 36 new funds were issued, an increase of 28 from the previous period, including 15 active equity - biased funds and 10 passive index funds. The 10 passive index funds were all stock - type, mainly tracking indices such as the CSI Battery Theme, Hang Seng Biotechnology, ChiNext 50, and agriculture, forestry, animal husbandry and fishery. Currently, the issuance share of active equity funds is still at a historical low, but there has been an obvious upward trend since this year. - Five new funds were established last week, a decrease of 59 from the previous period. New funds raised a total of 1.451 billion yuan, a decrease of 56.879 billion yuan from the previous period. The E Fund CSI Battery Theme ETF managed by Li Xu had the largest raised scale of about 859 million yuan [54][59].

2026 年 3 月 A 股重点指数调样公告解读 1 、 《 缠 论 技 术 分 析 框 架 解 析 》 2026-02-12 2、《2026 年 3 月 A 股重点指数调样 预测及投资机会解读》2026-02-07 3、《主动权益基金 2025 四季度持仓 解析》2026-01-23 证券研究报告/金融工程专题报告 2026 年 03 月 01 日 分析师：何青青 执业证书编号：S0740525070007 Email：heqq@zts.com.cn 分析师：吴先兴 执业证书编号：S0740525110003 Email：wuxx02@zts.com.cn 报告摘要 3 月指数样本股调整在即，把握事件窗口期 2026 年 2 月 27 日，中证指数公司公布了 3 月 16 日即将生效的指数定期调样名单。 本次定期调样涉及的重点指数为科创 50、科创创业 50、科创 100、红利低波 100、 北证 50。我们定量测算了相关个股的影响，供投资者参考。 基于最新调样公告的个股冲击测算 相关报告 基于中证指数公司公布的拟调样名单，结合近期交易数据及指数权重规则，我们汇总 估算了 5 个指数调样对个股的综合冲击。其 ...

近日，君实生物发布公告称，2025年度主要财务数据初步核算显示，公司营业总收入为24.98亿元，同 比增长28.23%。报告期内，归母净利润约亏损8.74亿元，较上年同期亏损12.81亿元有所改善。 公告中提到，公司核心产品特瑞普利单抗注射液（拓益®）在国内市场销售收入同比大幅增长约 37.72%。截至公告披露日，拓益®已在中国内地获批上市的适应症全部纳入国家医保目录，并在全球多 个国家和地区获得上市批准。公司实施股票期权激励计划，虽然股份支付费用增加，但通过加强费用管 控和资源聚焦，归母净亏损金额显著缩窄。 (编辑：杨燕 林辰)关键字： 医疗 （君实生物公告） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以上海君实生物 医药科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币万元 ■ 报告期内，公司核心产品特瑞普利单抗注射液（商品名：拓益?）于国内市场销售收入同比大幅增长约 37.72%。截至本公告披露日，拓益?已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目 录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 公司亦持续拓展全球商业化网络，截至本公告披露日，特瑞普利单抗已在中国内地、中国香港、美国、 欧盟、印度、英国、澳大利亚和新加坡等40多个国家和地区获批上市，并在全球多个国家和地区接受上 市审评。 随着已获批产品和适应症纳入国家医保目录后可及性的提高，未来更多产品和适应症的陆续获批上市， 以及持续不断的全球市场商业化拓展，公司的商业化竞争力将获得持续提升。 2025年度，公司持续落实 ...

今日热点导览 TOP 3 大新闻 语音误关大灯致车祸，领克致歉 近日，一车主驾驶领克Z20夜间在高速上行驶时，语音操作误关大灯致车辆撞上护栏一事引发网友广泛关注。针对此事，领克汽车销售有限公司副总经理 穆军通过社交平台进行回应。2月26日，穆军在其个人微博发文称："昨晚发生一起领克Z20车辆行驶中语音误操作控制关闭大灯的情况，今天我们第一时 间完成了语音控制优化方案，现已通过云端推送更新，后续在行驶状态下只能通过手动控制大灯关闭，请大家放心。感谢用户的反馈与监督，对此带来的 困扰我们深表歉意，领克始终守护您的安全。"（智通财经） OpenAI获得1100亿美元融资 OpenAI宣布获得新融资1100亿美元，其中300亿美元来自软银，300亿美元来自英伟达，500亿美元来自亚马逊，投前估值7300亿美元。OpenAI称，公司还 与亚马逊签署了战略合作伙伴关系，并与英伟达签订了关于下一代推理计算的协议。随着这轮融资的进行，预计后续还会有更多金融投资者加入。（第一 财经） 图源：@财经网科技 大公司/大事件 豆包手机回应存在安全漏洞，并已升级了相应的防护措施 36氪获悉，豆包手机发布关于恶意炒作"豆包手机助手漏洞" ...

另一方面，科创50和科创100实现了体系内样本的有序互换，科创50调入样本来自科创100，而科创50调 出样本则相应转入科创100，二者协同联动共同表征科创板大中市值证券表现。科创50与科创100实现对 科创板六大行业全面覆盖，新兴行业结构多元，科创50新一代信息技术行业权重提升约2%，科创100新 材料、生物医药等其他行业提升约4%。 近年来，上交所持续完善"一体两翼"指数体系，加快提升指数体系质量和多样性，强化服务新质生产力 发展和高水平科技自立自强的能力，有效支持中长期资金入市，服务国家重点战略落地。 2月27日，中证指数有限公司发布关于科创50等指数一季度定期调整结果的公告。根据指数编制规则， 科创50等科创指数样本每季度进行定期调整，本次调整将于3月13日收市后实施。 科大国盾量子技术股份有限公司、深圳中科飞测科技股份有限公司、中科星图股份有限公司将被调入科 创50指数，北京热景生物技术股份有限公司、陕西斯瑞新材料股份有限公司、上海君实生物医药科技股 份有限公司等10只证券将被调入科创100指数。 此次样本调整后，一方面，科创宽基指数对科创板市场的代表性进一步提升。调整后，科创50指数总市 值4.5 ...

资料显示，公司主营类生物制品。 报告期内，公司核心产品特瑞普利单抗注射液（商品名：拓益®）于国内市场销售收入同比大幅增长约 37.72%。截至本公告披露日，拓益®已在中国内地获 批上市的 12 项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗 PD-1 单抗药物。 公司亦持续拓展全球商业化网络，截至本公告披露日，特瑞普利单抗已在中国内地、中国香港、美国、欧盟、印度、英国、澳大利亚和新加坡等40 多个国 家和地区获批上市，并在全球多个国家和地区接受上市审评。 中证智能财讯君实生物（688180）2月27日晚间披露2025年业绩快报，公司实现营业收入24.98亿元，同比增长28.23%；归母净利润亏损8.74亿元，上年同期 亏损12.81亿元；扣非净利润亏损9.89亿元，上年同期亏损12.9亿元；基本每股收益-0.87元，加权平均净资产收益率为-14.7%。以最新收盘价计算，市净率 （LF）约5.62倍，市销率（TTM）约14.06倍。 以本次披露业绩快报数据计算，公司近年市盈率（TTM）图如下所示： 市净率=总市值/净资产。市净率估值法多用于盈利波动较大而净资产相对稳定的公司。 ...

国家药监局：2025年共收到创新医疗器械特别审批申请457项 近日，国家药监局发布2025年度创新医疗器械等产品注册审批情况。2025年，国家药监局按照《创新医 疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗器械 特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26项获 准优先审批。 国家药监局：2025年475个中药材生产基地通过检查 央视新闻消息显示，记者从2026年全国中药注册管理和质量安全监管工作会上了解到：截至2025年年 底，全国475个中药材生产基地通过延伸检查，种植面积近124万亩，可以提供101种中药材，供给215家 中药生产企业生产275个品种。国家药监局表示，2025年监管部门聚焦中药风险预警，督促中药生产企 业主动强化监测预警，及时采取措施有效控制风险、消除隐患。完善中药说明书安全性信息，印发《已 上市中药变更药品说明书中安全性内容的申报资料撰写要求》。发布5批公告，涉及666个批准文号，完 成相关补充申请21个。 药械审批 上海医药：普瑞巴林胶囊获得菲律宾药品注册证书 2月27日，上海医药(60160 ...